Research

The Duarte Laboratory Group primarily focuses on the following major areas of research:

• Clinical trials and implementation research on pharmacogenetic testing, particularly in medically underserved patient populations
• Genomic and transcriptomic predictors of disease severity and clinical outcomes in patients with left heart failure
• Genomic and transcriptomic predictors of disease severity and clinical outcomes in patients with pulmonary hypertension
• Pharmacological modulators of disease severity in heart failure with preserved ejection fraction

Publications

• 2025
  CYP2C19 Phenotype, P2Y 12 Inhibitor Selection, and Clinical Outcomes in Patients on Maintenance Clopidogrel Therapy
  Journal of the American Heart Association. 14(14) [DOI] 10.1161/jaha.125.041634.
  Publisher’s Site

• 2025
  Dapagliflozin enhances systolic and diastolic function in concordance with clinical response in patients with left ventricular dysfunction.
  European review for medical and pharmacological sciences. 29(5):231-247 [DOI] 10.26355/eurrev_202505_37222. [PMID] 40444607.
  PubMed · Publisher’s Site

• 2025
  Development of an Ancestrally Inclusive Preemptive Pharmacogenetic Testing Panel
  Clinical and Translational Science. 18(5) [DOI] 10.1111/cts.70230.
  Publisher’s Site

• 2025
  Disparities in Clinical Outcomes Observed Within Electronic Health Record Data From a Statewide Cohort of Pulmonary Arterial Hypertension Patients
  Pulmonary Circulation. 15(1) [DOI] 10.1002/pul2.70041.
  Publisher’s Site

• 2025
  Fatty acid desaturase genetic variations in heart failure and cardiovascular disease.
  American heart journal plus : cardiology research and practice. 53 [DOI] 10.1016/j.ahjo.2025.100529. [PMID] 40212288.
  PubMed · Publisher’s Site

• 2025
  Genetic polymorphisms in SLC5A2 are associated with clinical outcomes and dapagliflozin response in heart failure patients.
  Frontiers in pharmacology. 16 [DOI] 10.3389/fphar.2025.1539870. [PMID] 40356983.
  PubMed · Publisher’s Site

• 2025
  Genetic variation in RYR1 is associated with heart failure progression and mortality in a diverse patient population.
  Frontiers in cardiovascular medicine. 12 [DOI] 10.3389/fcvm.2025.1529114. [PMID] 40060969.
  PubMed · Publisher’s Site

• 2025
  Implementation of clinical pharmacogenetic testing in medically underserved patients: a narrative review.
  Pharmacogenomics. 26(3-4):107-119 [DOI] 10.1080/14622416.2025.2490461. [PMID] 40211878.
  PubMed · Publisher’s Site

• 2025
  Implementing Pharmacogenomics Clinical Decision Support: A Comprehensive Tutorial on how to Integrate the Epic Genomics Module
  Clinical Pharmacology & Therapeutics. 117(6):1670-1681 [DOI] 10.1002/cpt.3599.
  Publisher’s Site

• 2025
  Lack of association between genetic variations in CYP3A5 and blood pressure or hypertension risk in the UK biobank.
  Frontiers in genetics. 16 [DOI] 10.3389/fgene.2025.1490863. [PMID] 40463714.
  PubMed · Publisher’s Site

• 2024
  Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta‐Blocker Therapy
  Clinical Pharmacology & Therapeutics. 116(4):939-947 [DOI] 10.1002/cpt.3351.
  Publisher’s Site

• 2024
  CYP2C19 Genotype Is Associated With Adverse Cardiovascular Outcomes in Black Patients Treated With Clopidogrel Undergoing Percutaneous Coronary Intervention
  Journal of the American Heart Association. 13(12) [DOI] 10.1161/jaha.123.033791.
  Publisher’s Site

• 2024
  Deficiency of the Deubiquitinase UCHL1 Attenuates Pulmonary Arterial Hypertension
  Circulation. 150(4):302-316 [DOI] 10.1161/circulationaha.123.065304.
  Publisher’s Site

• 2024
  Effectiveness of Clopidogrel vs Alternative P2Y12 Inhibitors Based on the ABCD-GENE Score.
  Journal of the American College of Cardiology. 83(15):1370-1381 [DOI] 10.1016/j.jacc.2024.02.015. [PMID] 38599713.
  PubMed · Publisher’s Site

• 2024
  Enhancing the Integration of Pre-Emptive Pharmacogenetic (PGx) Testing in Primary Care: Prioritizing Underserved Patients’ Preferences in Implementation. Journal of personalized medicine. 14(12) [DOI] 10.3390/jpm14121128. [PMID] 39728041.
  PubMed · Publisher’s Site

• 2024
  Estimating preferences and willingness to pay for pharmacogenetic testing in populations who are medically underserved: a discrete choice experiment.
  Frontiers in pharmacology. 15 [DOI] 10.3389/fphar.2024.1384667. [PMID] 38595920.
  PubMed · Publisher’s Site

• 2024
  Evaluating the Effect of Estimating Renal Function With the CKD‐EPI 2021 Equation on the ABCD‐GENE Score for Clopidogrel Response Prediction
  Clinical Pharmacology & Therapeutics. 116(5):1227-1230 [DOI] 10.1002/cpt.3385.
  Publisher’s Site

• 2024
  Feasibility of preemptive pharmacogenetic testing and improvement of medication treatment satisfaction among medically underserved patients
  Clinical and Translational Science. 17(1) [DOI] 10.1111/cts.13692.
  Publisher’s Site

• 2024
  Leveraging QSP Models for MIPD: A Case Study for Warfarin/INR
  Clinical Pharmacology & Therapeutics. 116(3):795-806 [DOI] 10.1002/cpt.3274.
  Publisher’s Site

• 2024
  Omega-3 fatty acids in the treatment of heart failure.
  Current problems in cardiology. 49(9) [DOI] 10.1016/j.cpcardiol.2024.102730. [PMID] 38950721.
  PubMed · Publisher’s Site

• 2024
  Plasma Proteomics Identifies B2M as a Regulator of Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction
  Arteriosclerosis, Thrombosis, and Vascular Biology. 44(7):1570-1583 [DOI] 10.1161/atvbaha.123.320270.
  Publisher’s Site

• 2024
  Using Omics to Identify Novel Therapeutic Targets in Heart Failure
  Circulation: Genomic and Precision Medicine. 17(3) [DOI] 10.1161/circgen.123.004398.
  Publisher’s Site

• 2023
  An Introductory Tutorial on Cardiovascular Pharmacogenetics for Healthcare Providers
  Clinical Pharmacology & Therapeutics. 114(2):275-287 [DOI] 10.1002/cpt.2957.
  Publisher’s Site

• 2023
  Evaluation of Potential Racial Disparities in CYP2C19-Guided P2Y12 Inhibitor Prescribing After Percutaneous Coronary Intervention.
  Clinical pharmacology and therapeutics. 113(3):615-623 [DOI] 10.1002/cpt.2776. [PMID] 36306392.
  PubMed · Publisher’s Site

• 2023
  Pharmacist-Guided Pharmacogenetic Service Lowered Warfarin-Related Hospitalizations
  Pharmacogenomics. 24(6):303-314 [DOI] 10.2217/pgs-2023-0014.
  Publisher’s Site

• 2022
  Changing from mandatory to optional genotyping results in higher acceptance of pharmacist-guided warfarin dosing.
  Pharmacogenomics. 23(2):85-95 [DOI] 10.2217/pgs-2021-0109. [PMID] 35001645.
  PubMed · Publisher’s Site

• 2022
  CYP2C19 Genotype‐Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings
  Journal of the American Heart Association. 11(4) [DOI] 10.1161/jaha.121.024159.
  Publisher’s Site

• 2022
  Exploring perceptions, knowledge, and attitudes regarding pharmacogenetic testing in the medically underserved.
  Frontiers in genetics. 13 [DOI] 10.3389/fgene.2022.1085994. [PMID] 36712853.
  PubMed · Publisher’s Site

• 2022
  Genetic polymorphisms in ADRB2 and ADRB1 are associated with differential survival in heart failure patients taking β-blockers
  The Pharmacogenomics Journal. 22(1):62-68 [DOI] 10.1038/s41397-021-00257-1.
  Publisher’s Site

• 2022
  Patients’ Perspectives of Factors That Influence Pharmacogenetic Testing Uptake: Enhancing Patient Counseling and Results Dissemination.
  Journal of personalized medicine. 12(12) [DOI] 10.3390/jpm12122046. [PMID] 36556266.
  PubMed · Publisher’s Site

• 2022
  Sex-dimorphic gene effects on survival outcomes in people with coronary artery disease.
  American heart journal plus : cardiology research and practice. 17 [DOI] 10.1016/j.ahjo.2022.100152. [PMID] 35959094.
  PubMed · Publisher’s Site

• 2022
  β1-receptor polymorphisms and junctional ectopic tachycardia in children after cardiac surgery.
  Clinical and translational science. 15(3):619-625 [DOI] 10.1111/cts.13178. [PMID] 34713976.
  PubMed · Publisher’s Site

• 2021
  County-level longitudinal clustering of COVID-19 mortality to incidence ratio in the United States.
  Scientific reports. 11(1) [DOI] 10.1038/s41598-021-82384-0. [PMID] 33542313.
  PubMed · Publisher’s Site

• 2021
  Cox-sMBPLS: An Algorithm for Disease Survival Prediction and Multi-Omics Module Discovery Incorporating Cis-Regulatory Quantitative Effects.
  Frontiers in genetics. 12 [DOI] 10.3389/fgene.2021.701405. [PMID] 34408773.
  PubMed · Publisher’s Site

• 2021
  IL-18 mediates sickle cell cardiomyopathy and ventricular arrhythmias.
  Blood. 137(9):1208-1218 [DOI] 10.1182/blood.2020005944. [PMID] 33181835.
  PubMed · Publisher’s Site

• 2021
  Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
  Clinical pharmacology and therapeutics. 109(3):705-715 [DOI] 10.1002/cpt.2039. [PMID] 32897581.
  PubMed · Publisher’s Site

• 2021
  Multisite investigation of strategies for the clinical implementation of pre-emptive pharmacogenetic testing
  Genetics in Medicine. 23(12):2335-2341 [DOI] 10.1038/s41436-021-01269-9.
  Publisher’s Site

• 2021
  NR3C2 genotype is associated with response to spironolactone in diastolic heart failure patients from the Aldo-DHF trial.
  Pharmacotherapy. 41(12):978-987 [DOI] 10.1002/phar.2626. [PMID] 34569641.
  PubMed · Publisher’s Site

• 2021
  Patients with geographic barriers to health care access are prescribed a higher proportion of drugs with pharmacogenetic testing guidelines.
  Clinical and translational science. 14(5):1841-1852 [DOI] 10.1111/cts.13032. [PMID] 33955180.
  PubMed · Publisher’s Site

• 2021
  Pharmacogenetics to guide cardiovascular drug therapy.
  Nature reviews. Cardiology. 18(9):649-665 [DOI] 10.1038/s41569-021-00549-w. [PMID] 33953382.
  PubMed · Publisher’s Site

• 2021
  Therapeutic Challenges and Emerging Treatment Targets for Pulmonary Hypertension in Left Heart Disease
  Journal of the American Heart Association. 10(11) [DOI] 10.1161/jaha.120.020633.
  Publisher’s Site

• 2020
  Beta-Blocker Dose Stratifies Mortality Risk in a Racially Diverse Heart Failure Population.
  Journal of cardiovascular pharmacology. 75(3):250-258 [DOI] 10.1097/FJC.0000000000000779. [PMID] 31895871.
  PubMed · Publisher’s Site

• 2020
  Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data.
  The pharmacogenomics journal. 20(5):724-735 [DOI] 10.1038/s41397-020-0162-5. [PMID] 32042096.
  PubMed · Publisher’s Site

• 2019
  Determinants of Cytochrome P450 2D6 mRNA Levels in Healthy Human Liver Tissue.
  Clinical and translational science. 12(4):416-423 [DOI] 10.1111/cts.12632. [PMID] 30821899.
  PubMed · Publisher’s Site

• 2019
  Transcriptome-wide analysis associates ID2 expression with combined pre- and post-capillary pulmonary hypertension.
  Scientific reports. 9(1) [DOI] 10.1038/s41598-019-55700-y. [PMID] 31862991.
  PubMed · Publisher’s Site

• 2018
  Association of Genetic Variants With Warfarin-Associated Bleeding Among Patients of African Descent.
  JAMA. 320(16):1670-1677 [DOI] 10.1001/jama.2018.14955. [PMID] 30357299.
  PubMed · Publisher’s Site

• 2018
  CYP2D6 Protein Level Is the Major Contributor to Interindividual Variability in CYP2D6-Mediated Drug Metabolism in Healthy Human Liver Tissue.
  Clinical pharmacology and therapeutics. 104(5):974-982 [DOI] 10.1002/cpt.1032. [PMID] 29349771.
  PubMed · Publisher’s Site

• 2018
  Endothelial nitric oxide synthase genotype is associated with pulmonary hypertension severity in left heart failure patients.
  Pulmonary circulation. 8(2) [DOI] 10.1177/2045894018773049. [PMID] 29718770.
  PubMed · Publisher’s Site

• 2017
  Anticoagulation endpoints with clinical implementation of warfarin pharmacogenetic dosing in a real-world setting: A proposal for a new pharmacogenetic dosing approach.
  Clinical pharmacology and therapeutics. 101(5):675-683 [DOI] 10.1002/cpt.558. [PMID] 28032893.
  PubMed · Publisher’s Site

• 2017
  The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real-World Setting.
  Clinical and translational science. 10(3):143-146 [DOI] 10.1111/cts.12456. [PMID] 28294551.
  PubMed · Publisher’s Site

• 2016
  Circulating Procollagen Type III N-Terminal Peptide and Mortality Risk in African Americans With Heart Failure
  Journal of cardiac failure. 22(9):692-699 [DOI] 10.1016/j.cardfail.2015.12.016. [PMID] 26721774.
  PubMed · Publisher’s Site

• 2016
  Clopidogrel pharmacogenetics: from evidence to implementation.
  Future cardiology. 12(5):511-4 [DOI] 10.2217/fca-2016-0045. [PMID] 27539287.
  PubMed · Publisher’s Site

• 2016
  Genome-Wide Analysis Identifies IL-18 and FUCA2 as Novel Genes Associated with Diastolic Function in African Americans with Sickle Cell Disease
  PLOS ONE. 11(9) [DOI] 10.1371/journal.pone.0163013.
  Publisher’s Site

• 2016
  Implementation of Inpatient Models of Pharmacogenetics Programs
  American Journal of Health-System Pharmacy. 73(23):1944-1954 [DOI] 10.2146/ajhp150946. [PMID] 27864202.
  PubMed · Publisher’s Site

• 2016
  Implementing Pharmacogenomics at Your Institution: Establishment and Overcoming Implementation Challenges.
  Clinical and translational science. 9(5):233-245 [DOI] 10.1111/cts.12404. [PMID] 27214750.
  PubMed · Publisher’s Site